^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GSK2302032A

    i
    Associations
    News

    Trials

    Company:
    Agenus, GSK
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer (NCT01149343)
    Phase 1
    GlaxoSmithKline
    Completed
    Last update posted :
    11/20/2020
    Initiation :
    07/02/2010
    Primary completion :
    02/11/2014
    Completion :
    12/19/2016
    PRAME
    |
    PRAME expression
    |
    GSK2302025A • GSK2302032A
    A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor (PEARL) (NCT01853878)
    Phase 2
    GlaxoSmithKline
    Completed
    Last update posted :
    08/28/2019
    Initiation :
    06/12/2013
    Primary completion :
    08/24/2016
    Completion :
    08/24/2016
    PRAME
    |
    PRAME expression
    |
    GSK2302032A